preclinical-research
(3)
Reza Rezaei Built a Career at the Handoff Between Science and Sales
A veterinarian and animal scientist learned to translate laboratory detail into commercial trust. After a decade climbing Cyagen's ranks, Reza Rezaei now leads the company from the junction of research, customers and scale.
Andrew Reaume
Andrew Reaume is the co-founder, President and CEO of Melior Discovery, an Exton, Pennsylvania preclinical contract research organization built around theraTRACE, a multiplexed in vivo phenotypic screening platform that runs a single drug candidate through a battery of animal disease models at once to uncover unexpected therapeutic uses. A geneticist by training with a Wharton MBA, he conceived the idea at Pfizer, left in 2005 to build it, and has since raised over $15 million in capital, closed more than $40 million in partnering deals, and pushed a repurposed compound, MLR-1023, into Phase 2 diabetes trials.
Linh Hoang
Linh Hoang, MD, PhD, is the Chief Executive Officer of HistoWiz, the New York based digital pathology company building PathologyMap, a platform that automates histology and connects researchers to top pathologists on demand. A physician-scientist turned operator, he trained at the University of Pennsylvania, cut his teeth at Boston Consulting Group, and ran businesses at Thermo Fisher and PerkinElmer before leading two diagnostics companies as CEO, Boston Microfluidics and its successor Weavr Health, ahead of joining HistoWiz in October 2022.